Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China
Tislelizumab plus chemotherapy demonstrates cost-effectiveness in the first-line treatment of ES-SCLC in China. This study provides preliminary evidence for the economic value of tislelizumab in the treatment of ES-SCLC, supporting its consideration as a first-line therapeutic option.
Authors
- Hong Tang (ORCID: https://orcid.org/0000-0002-4224-3575)
- S. Joe Qin (ORCID: https://orcid.org/0000-0001-7631-2535)
- Feng Xue (ORCID: https://orcid.org/0000-0002-5992-5927)
- Xiao Li (ORCID: https://orcid.org/0000-0003-1992-3529)
- Fangfang Chen (ORCID: https://orcid.org/0000-0002-0854-1667)
- Jie Peng (ORCID: https://orcid.org/0000-0001-8907-701X)
- Jing Bai (ORCID: https://orcid.org/0000-0002-1772-2179)
Institutions
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fpubh.2025.1552734
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China